Dihexa for PCOS / PMOS Brain Fog The 12 May 2026 Lancet global-consensus PMOS rename (Polyendocrine Metabolic Ovarian Syndrome) led by the Endocrine Society, the International Androgen Excess & PCOS Society and Verity (UK PCOS Charity) across 56 organisations and 14,300 survey responses
With the oral version, Rybelsus, less of the medication makes it into the body because it must go through the digestive system first
WW, RC, SG, TBJ and BL are guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis
In our November review, Nutrition Insight highlights some of the months biggest stories, including breakthrough GLP-1 research and drug development, our discussion with AAK on the impact of supply chains on nutrition innovation, and Novonesis latest insights into microbiome-focused healthy longevity innovations
A DSEA pathways analyses suggests these drugs upregulate secretion and activate pathways related to cell-cell, cell-matrix interactions, neuronal survival and differentiation suggesting possible new mechanistic targets for designing novel radioprotective drugs
.png)
